Literature DB >> 2672095

Current status of MR imaging contrast agents: special report.

G L Wolf1.   

Abstract

The first contrast agent for magnetic resonance imaging has been available for clinical use in the United States for just over 1 year. It has been widely adopted for a variety of indications with apparent safety. Several other agents are in clinical trials and are reviewed here.

Mesh：

Substances：

Year:  1989        PMID： 2672095     DOI： 10.1148/radiology.172.3.2672095

Source DB:  PubMed          Journal:  Radiology        ISSN： 0033-8419            Impact factor:   11.105


  4 in total

1.  3D bioprinting of tissues and organs.

Authors:  Sean V Murphy; Anthony Atala
Journal:  Nat Biotechnol       Date:  2014-08       Impact factor: 54.908

2.  Randomised double blind trial of the safety and efficacy of two gadolinium complexes (Gd-DTPA and Gd-DOTA).

Authors:  P Brugières; A Gaston; H R Degryse; P M Parizel; A M de Schepper; I Berry; C Manelfe; F Le Bras; C Marsault; W Wichmann
Journal:  Neuroradiology       Date:  1994       Impact factor: 2.804

Review 3.  The clinical application of radiopharmaceuticals.

Authors:  N E Leeds
Journal:  Drugs       Date:  1990-11       Impact factor: 9.546

4.  Use of trimetasphere metallofullerene MRI contrast agent for the non-invasive longitudinal tracking of stem cells in the lung.

Authors:  Sean V Murphy; Austin Hale; Tanya Reid; John Olson; Amritha Kidiyoor; Josh Tan; Zhiguo Zhou; John Jackson; Anthony Atala
Journal:  Methods       Date:  2015-11-10       Impact factor: 3.608
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.